TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39052701

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination (Rotarix)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 184
Study: 39052716

Group type: EXPERIMENTAL
Intervention: RSM01, an investigational anti-RSV prefusion F monoclonal antibody (mAb); details on dosage and duration not available.
Number of subjects: 0
Study: 39052715

Group type: EXPERIMENTAL
Intervention: 3-day azithromycin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive treatment (control)
Number of subjects: 0
Study: 39052718

Group type: EXPERIMENTAL
Intervention: NVX-CoV2515
Number of subjects: 829

Group type: COMPARATOR
Intervention: NVX-CoV2373
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Bivalent mixture
Number of subjects: 829
Study: 39052726

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Number of subjects: 1653
Study: 39052748

Group type: EXPERIMENTAL
Intervention: Cabotegravir plus rilpivirine (CAB + RPV)
Number of subjects: 1245
Study: 39052893

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) surgery with audible ECochG monitoring
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cochlear Implant (CI) surgery without audible ECochG monitoring
Number of subjects: 87
Study: 39053009

Group type: EXPERIMENTAL
Intervention: Video-based coaching (VBC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard gynecology curriculum (control group)
Number of subjects: 28
Study: 39053010

Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis for fetal antigen genotyping
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis for antigens K1, E, C, Fy a, c, D(RhD)
Number of subjects: 156
Study: 39053011

Group type: EXPERIMENTAL
Intervention: Panniculus retractor device
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 39053295

Group type: EXPERIMENTAL
Intervention: Pandemic-adjusted family/systemic constellation therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 39053611

Group type: EXPERIMENTAL
Intervention: Deuruxolitinib 8 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deuruxolitinib 12 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39053653

Group type: EXPERIMENTAL
Intervention: Water exchange cap-assisted colonoscopy (WECAC)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Water exchange (WE)
Number of subjects: 280
Study: 39053696

Group type: EXPERIMENTAL
Intervention: MNA <17
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MNA, SGA, SNAQ
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MNA
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SGA
Number of subjects: 300
Study: 39053878

Group type: EXPERIMENTAL
Intervention: Short abutments (SA < 2 mm)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Long abutments (LA > 2 mm)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subcrestal ≈2 mm implants with LA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Subcrestal ≈1 mm position with LA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subcrestal implants
Number of subjects: 26
Study: 39053924

Group type: EXPERIMENTAL
Intervention: Video-based firearm safety education
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control group (baseline survey about child safety behaviours)
Number of subjects: 371
Study: 39053948

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg plus background csDMARD(s)
Number of subjects: 229
Study: 39053954

Group type: EXPERIMENTAL
Intervention: Allopurinol (200-500 mg daily)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Placebo (equivalent dose)
Number of subjects: 1116
Study: 39053958

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Rapid analysis framework
Number of subjects: 92
Study: 39053957

Group type: EXPERIMENTAL
Intervention: BETTER Women programme with a trained peer health coach providing ongoing support after receipt of a BETTER prevention prescription.
Number of subjects: 408

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the wait period).
Number of subjects: 408
Study: 39053960

Group type: EXPERIMENTAL
Intervention: 30 mg/kg AMK injection on the first and fourth day of treatment
Number of subjects: 20
Study: 39053961

Group type: EXPERIMENTAL
Intervention: Early pharmacotherapeutic treatment of clinically symptomatic and echocardiography-confirmed haemodynamically significant PDA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39053972

Group type: EXPERIMENTAL
Intervention: Patients living with frailty (CFS≥5)
Number of subjects: 1840
Study: 39054302

Group type: EXPERIMENTAL
Intervention: Cellular Bone Allograft (CBA; Trinity Elite)
Number of subjects: 252
Study: 39054326

Group type: EXPERIMENTAL
Intervention: Metacognitive Training-Silver (MCT-Silver)
Number of subjects: 38
Study: 39054374

Group type: EXPERIMENTAL
Intervention: 9-month supervised exercise program
Number of subjects: 357

Group type: COMPARATOR
Intervention: usual care (control group)
Number of subjects: 357
Study: 39054420

Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin-System (RAS) blockers with beta-blockers and optionally spironolactone
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Coronary heart disease
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 252
Study: 39054425

Group type: EXPERIMENTAL
Intervention: Costoclavicular lateral approach (Group CLB)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Costoclavicular medial approach (Group CMB)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Lateral sagittal technique (Group LSB)
Number of subjects: 56
Study: 39054430

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus epacadostat
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sunitinib/pazopanib
Number of subjects: 129
Study: 39054460

Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE) followed by reduced dose MR guided Radiation Therapy (MRgRT) with either 32.5 Gy in 5 Fractions or 22 Gy in 2 fractions
Number of subjects: 42
Study: 39054462

Group type: EXPERIMENTAL
Intervention: E + P + C (epacadostat 100 mg BID + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Number of subjects: 178

Group type: COMPARATOR
Intervention: PBO + P + C (placebo + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: E + P + C
Number of subjects: 178

Group type: COMPARATOR
Intervention: PBO + P + C
Number of subjects: 178
Study: 39054467

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus epacadostat
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: EXTREME regimen
Number of subjects: 89
Study: 39054476

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 21 days plus oral epacadostat 100 mg twice daily (combination)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab (control)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study: 39054479

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) with integrated multi-omics data (radiomics, gut microbiota, ctDNA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 0
Study: 39054485

Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg BID plus pembrolizumab
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab
Number of subjects: 42
Study: 39054491

Group type: EXPERIMENTAL
Intervention: epacadostat plus pembrolizumab
Number of subjects: 93

Group type: COMPARATOR
Intervention: placebo plus pembrolizumab
Number of subjects: 93
Study: 39054496

Group type: EXPERIMENTAL
Intervention: Stakeholder insights on barriers and facilitators to healthy lifestyle behaviours
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: School environment as a facilitator
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Collaboration with community and governmental stakeholders
Number of subjects: 28
Study: 39054511

Group type: EXPERIMENTAL
Intervention: ICU survivors admitted after a cerebrovascular accident, intracerebral hemorrhage, or (neuro)trauma
Number of subjects: 3913

Group type: EXPERIMENTAL
Intervention: ICU survivors admitted due to respiratory disease
Number of subjects: 3913

Group type: EXPERIMENTAL
Intervention: ICU survivors admitted due to trauma
Number of subjects: 3913

Group type: EXPERIMENTAL
Intervention: All studied 22 subgroups of ICU survivors
Number of subjects: 3913
Study: 39054514

Group type: EXPERIMENTAL
Intervention: Exercise combined with Manual Therapy (MT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise combined with Kinesiotaping (KT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Core stability exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control-motor training
Number of subjects: 0
Study: 39054596

Group type: EXPERIMENTAL
Intervention: Opium tincture
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 39054745

Group type: EXPERIMENTAL
Intervention: Community First Responders attending emergencies in rural areas
Number of subjects: 4500000

Group type: EXPERIMENTAL
Intervention: Community First Responder falls response
Number of subjects: 4500000

Group type: EXPERIMENTAL
Intervention: Community First Responders' involvement in high-priority emergency calls
Number of subjects: 4500000

Group type: EXPERIMENTAL
Intervention: Community First Responders' impact on out-of-hospital cardiac arrest outcomes
Number of subjects: 4500000

Group type: EXPERIMENTAL
Intervention: Community First Responders' training and support
Number of subjects: 4500000
Study: 39054763

Group type: EXPERIMENTAL
Intervention: Combined exercise (EX) program, 3 days/week for 20 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 112
Study: 39054765

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT: 80%-100% HRR)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Training (MIT: 60%-70% HRR)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Passive Control Group (CON)
Number of subjects: 121
Study: 39054770

Group type: EXPERIMENTAL
Intervention: (2R,6R)-Hydroxynorketamine (RR-HNK) at doses of 0.1-4 mg/kg (SAD) and 1-2 mg/kg (MAD) administered via IV over 40 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (2R,6R)-Hydroxynorketamine (RR-HNK)
Number of subjects: 0
Study: 39055378

Group type: EXPERIMENTAL
Intervention: Catenary curve-based extended depth of focus (EDOF) contact lens
Number of subjects: 24
Study: 39055379

Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Eye (CT)
Number of subjects: 22
Study: 39055495

Group type: EXPERIMENTAL
Intervention: Combination therapy of utidelone and capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 0
Study: 39055663

Group type: EXPERIMENTAL
Intervention: Early oral β-blocker therapy
Number of subjects: 1084

Group type: COMPARATOR
Intervention: No β-blocker therapy (Control)
Number of subjects: 1084
Study: 39055703

Group type: EXPERIMENTAL
Intervention: Two-drug regimen (2DR) - dolutegravir or darunavir/cobicistat + lamivudine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Three-drug regimen (3DR) - integrase inhibitor-based
Number of subjects: 100
Study: 39056160

Group type: EXPERIMENTAL
Intervention: IGU monotherapy (25 mg twice daily)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: IGU + MTX (10-15 mg weekly for MTX and 25 mg twice daily for IGU)
Number of subjects: 911

Group type: COMPARATOR
Intervention: MTX monotherapy (10-15 mg weekly)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: IGU monotherapy
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: IGU + MTX
Number of subjects: 911
Study: 39056338

Group type: EXPERIMENTAL
Intervention: AZD3427 (5, 15, or 45 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AZD3427 (subcutaneous injection)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AZD3427
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 39056349

Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 39057139

Group type: EXPERIMENTAL
Intervention: Local recurrence (LR)
Number of subjects: 1965

Group type: EXPERIMENTAL
Intervention: New metastatic disease (NM)
Number of subjects: 1965

Group type: EXPERIMENTAL
Intervention: Poor histological response (≥10% viable tumor)
Number of subjects: 1965

Group type: EXPERIMENTAL
Intervention: Axial tumor location
Number of subjects: 1965

Group type: EXPERIMENTAL
Intervention: Presence of lung metastases
Number of subjects: 1965

Group type: EXPERIMENTAL
Intervention: Poor versus good histological response
Number of subjects: 1965
Study: 39057291

Group type: EXPERIMENTAL
Intervention: Second-line axitinib treatment
Number of subjects: 0
Study: 39057551

Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 0
Study: 39058022

Group type: EXPERIMENTAL
Intervention: Cipargamin (intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39058315

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 163
Study: 39058367

Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily in continuous 28-day cycles)
Number of subjects: 19
Study: 39058490

Group type: EXPERIMENTAL
Intervention: 3% nicotine concentration (JUUL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2.4% nicotine concentration (NJOY)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5% nicotine concentration (JUUL or NJOY)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3% or 2.4% nicotine concentration sessions
Number of subjects: 50
Study: 39058662

Group type: EXPERIMENTAL
Intervention: QPOP-guided chemotherapy
Number of subjects: 10
Study: 39058740

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A (BoNT-A) injection into calf muscles
Number of subjects: 61

Group type: COMPARATOR
Intervention: 0.9% saline injection into calf muscles (placebo)
Number of subjects: 61
Study: 39058806

Group type: EXPERIMENTAL
Intervention: bio-etanercept
Number of subjects: 156

Group type: COMPARATOR
Intervention: O-etanercept
Number of subjects: 156
Study: 39058951

Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo plus immunochemotherapy (rituximab and bendamustine)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Copanlisib plus R-B
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo plus R-B
Number of subjects: 524
Study: 39058954

Group type: EXPERIMENTAL
Intervention: IXA-POM-DEX
Number of subjects: 30

Group type: COMPARATOR
Intervention: POM-DEX
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Crossover patients (from POM-DEX to IXA-POM-DEX)
Number of subjects: 30
Study: 39058966

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) added to multidrug chemotherapy
Number of subjects: 268

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 268
Study: 39058967

Group type: EXPERIMENTAL
Intervention: mHealth application for education and symptom management
Number of subjects: 22
Study: 39058968

Group type: EXPERIMENTAL
Intervention: Chemotherapy (2 cycles)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Irradiation (for 13 CNS lesions)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemotherapy (for lesions with adequate interim response)
Number of subjects: 45
Study: 39058972

Group type: EXPERIMENTAL
Intervention: Vebreltinib
Number of subjects: 52
Study: 39059033

Group type: EXPERIMENTAL
Intervention: PRO-CTCAE
Number of subjects: 303
Study: 39059184

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitor (CDK4/6i) therapy
Number of subjects: 2891

Group type: COMPARATOR
Intervention: Letrozole (upfront therapy)
Number of subjects: 2891
Study: 39059187

Group type: EXPERIMENTAL
Intervention: Higher concentrations of linoleic acid derived sEH (DiHOME) and CYP450 (EpOME) metabolites
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CYP450-sEH metabolites
Number of subjects: 112
Study: 39059373

Group type: EXPERIMENTAL
Intervention: Sildenafil cream, 3.6%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 39059389

Group type: EXPERIMENTAL
Intervention: Longitudinal cfEBV DNA tracking during neoadjuvant chemotherapy and radiotherapy
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Longitudinal cfEBV DNA tracking
Number of subjects: 1000
Study: 39059396

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 13
Study: 39059398

Group type: EXPERIMENTAL
Intervention: Foritinib (80, 120, 160, or 210 mg orally once daily over 21-day cycles in phase 2a; 160 mg in phase 2b)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Foritinib (160 mg orally once daily in phase 2b)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Foritinib
Number of subjects: 104
Study: 39059405

Group type: EXPERIMENTAL
Intervention: Anti-BCMA/GPRC5D bispecific CAR T cells
Number of subjects: 21
Study: 39059407

Group type: EXPERIMENTAL
Intervention: BIIB078 (5 mg, 10 mg, 20 mg, 35 mg, 60 mg, or 90 mg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BIIB078 (any dose)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 39059719

Group type: EXPERIMENTAL
Intervention: Emotion processing (face matching)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cognitive control over emotion (shape matching)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Age moderation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Hyperactivation in the right inferior parietal lobe
Number of subjects: 160
Study: 39059790

Group type: EXPERIMENTAL
Intervention: niPGT-A embryo culture protocol
Number of subjects: 428

Group type: COMPARATOR
Intervention: Standard invasive PGT-A culture protocol
Number of subjects: 428
Study: 39059804

Group type: EXPERIMENTAL
Intervention: Cholecystectomy (laparoscopic surgery)
Number of subjects: 0
Study: 39059887

Group type: EXPERIMENTAL
Intervention: Group 1 (wearable sensor alerts and self-testing)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Group 2 (self-testing only due to symptoms)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Group 3 (control group, no alerts or home testing)
Number of subjects: 450
Study: 39060019

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO+IPI)
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 1096
Study: 39060022

Group type: EXPERIMENTAL
Intervention: TG6050 (oncolytic vaccinia virus encoding hIL-12 and anti-CTLA-4 antibody)
Number of subjects: 0
Study: 39060125

Group type: EXPERIMENTAL
Intervention: TPG plus amantadine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo plus amantadine
Number of subjects: 100
Study: 39060169

Group type: EXPERIMENTAL
Intervention: Veinlite PEDI2
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All groups (including VR and Veinlite PEDI2)
Number of subjects: 160
Study: 39060170

Group type: EXPERIMENTAL
Intervention: White noise during nasal CPAP application
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine nasal CPAP application
Number of subjects: 80
Study: 39060172

Group type: EXPERIMENTAL
Intervention: Health Belief Model-based motivational interviews, web support, and follow-up (experimental group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study: 39060370

Group type: EXPERIMENTAL
Intervention: AB002 1.5 µg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AB002 3 µg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 39060373

Group type: EXPERIMENTAL
Intervention: Deep-learning-based method that fuses multi-modality images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available software-PMOD
Number of subjects: 0
Study: 39060374

Group type: EXPERIMENTAL
Intervention: CI-8993 (fully human IgG1κ monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human isotype IgG1 control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CI-8993
Number of subjects: 0
Study: 39060473

Group type: EXPERIMENTAL
Intervention: HP6V (violet LED and 6% hydrogen peroxide)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HP6B (blue LED and 6% hydrogen peroxide)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HP35V (violet LED and 35% hydrogen peroxide)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HP35B (blue LED and 35% hydrogen peroxide)
Number of subjects: 40
Study: 39060689

Group type: EXPERIMENTAL
Intervention: Gender-affirming chest masculinization surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oncologic risk-reducing mastectomies
Number of subjects: 0
Study: 39060701

Group type: EXPERIMENTAL
Intervention: PRF membrane transplantation (PMT group, n=21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional internal limiting membrane (ILM) peeling (IP group, n=19)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PRF membrane transplantation (PMT group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 39060905

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4362

Group type: COMPARATOR
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 4362